Information Provided By:
Fly News Breaks for December 30, 2019
BGNE
Dec 30, 2019 | 09:27 EDT
Guggenheim analyst Michael Schmidt said Chinese regulatory approval of tislelizumab for the treatment of patients with Hodgkin's lymphoma is in line with his expectation and may remove a "small overhang" on BeiGene shares. It is also important that approval came before the end of 2019, which qualifies tislelizumab for price negotiation and possible inclusion in the National Reimbursement Drug List in late 2020, Schmidt said. He keeps a Neutral rating on BeiGene shares.